



11/07/2005 | Press Release

DAVA Partners with IMPAX for the Distribution of Oxycodone HCL Extended-Release Tablets

Fort Lee, New Jersey, November 7, 2005 -- DAVA Pharmaceuticals, Inc. announced today that it has entered into a ten year agreement with IMPAX Laboratories, Inc. under which DAVA has been appointed the exclusive marketer and distributor of IMPAX's oxycodone HCl extended-release tablets C-II in 10, 20, 40 and 80 mg dosage strengths in the United States and Puerto Rico. Oxycodone HCl is the AB-rated generic equivalent version of Purdue Pharma L.P.'s OxyContin® that is indicated for the management of moderate-to-severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. The combined sales for the generic and branded versions of OxyContin® for the period ended August 31, 2005 were approximately \$1.8 billion according to NDCHealth.

"We are very pleased to enter into this long term partnership with IMPAX, one of the industry's foremost leaders in formulation, drug delivery technologies and drug development." said John H. Klein, DAVA's President and Chief Executive Officer. "I believe DAVA's oxycodone extended-release tablets are a valuable addition to our strategic portfolio of generic and specialty products, which DAVA will continue to build throughout 2005 and beyond."

About DAVA Pharmaceuticals

DAVA Pharmaceuticals, a specialty pharmaceuticals company, is focused on developing and marketing a broad portfolio of pharmaceutical products. DAVA is aggressively building its product portfolio through a combination of acquisitions, strategic alliances, in-licensing transactions, partnerships and development. DAVA's headquarters is in Fort Lee, New Jersey. For further information, please visit DAVA's website located at www.davapharma.com.